ADIL | tickerfilter.com

Fundamental analysis

46%

Profitability 35%

Dept financing 30%

Liquidity 50%

Performance 60%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.16%

1 Month

2.65%

3 Months

-17.47%

6 Months

-34.13%

1 Year

-59.47%

2 Year

-92.05%

Key data

Stock price

$0.68

P/E Ratio

0.00

DAY RANGE

$0.68 - $0.72

EPS

-$3.59

52 WEEK RANGE

$0.58 - $3.00

52 WEEK CHANGE

-$59.47

MARKET CAP

4.900 M

YIELD

N/A

SHARES OUTSTANDING

6.403 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-13-2025

BETA

0.84

PUBLIC FLOAT

AVERAGE 10 VOLUME

$29,505

AVERAGE 30 VOLUME

$44,618

Company detail

CEO: Cary J. Claiborne
Region: US
Website: adialpharma.com
Employees: 20
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction.

ADIL - ADIAL PHARMACEUTICALS, INC.